17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685

FOR IMMEDIATE RELEASE

Sun Pharma gets USFDA tentative approval for generic Gemzar® injection

Mumbai, March 5, 2008: Sun Pharmaceutical Industries Ltd. announced that USFDA has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for its generic version of Eli Lilly and Co's Gemzar®, gemcitabine injection.

These generic gemcitabine injections are therapeutic equivalents of Eli Lilly and Co's Gemzar® injections available in two strengths: 200 mg and 1 g single use vial. These strengths of gemcitabine injections have annual sales of approximately USD 680 million in the US.

Gemcitabine is an anticancer, used singly or in combination with other anticancer agents.

Gemzar® is a registered trademark of ***Eli Lilly and Co.***

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail mira.desai@sunpharma.com